Differential expression patterns of metastasis suppressor proteins in basal cell carcinoma

International Journal of Dermatology

Volumn 54, Issue 8, 2015, Pages 905-915

  Bozdogan, Onder ^a,b   Yulug, Isik G ^a   Vargel, Ibrahim ^c   Cavusoglu, Tarik ^b   Karabulut, Ayse A ^b   Karahan, Gurbet ^a   Sayar, Nilufer ^a  

^a BILKENT UNIVERSITY   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AKAP12 PROTEIN; CD82 ANTIGEN; METASTASIS SUPPRESSOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; N MYC DOWNSTREAM REGULATED I PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 2; UNCLASSIFIED DRUG; UVOMORULIN; AKAP12 PROTEIN, HUMAN; ARHGDIB PROTEIN, HUMAN; CADHERIN; CD82 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; MAP2K4 PROTEIN, HUMAN; N-MYC DOWNSTREAM-REGULATED GENE 1 PROTEIN; NME1 PROTEIN, HUMAN; NUCLEOSIDE DIPHOSPHATE KINASE NM23; SIGNAL PEPTIDE; TUMOR SUPPRESSOR PROTEIN;

AGED; ARTICLE; BASAL CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; CHEMISTRY; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY; SKIN; SKIN TUMOR;

A KINASE ANCHOR PROTEINS; AGED; ANTIGENS, CD82; CADHERINS; CARCINOMA, BASAL CELL; CELL CYCLE PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAP KINASE KINASE 4; MIDDLE AGED; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR BETA; SKIN; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84937027371     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12581     Document Type: Article

References (53)

1. Ting PT, Kasper R, Arlette JP. Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg 2005; 9: 10-15.
2. Varga E, Korom I, Rasko Z, et al. Neglected basal cell carcinomas in the 21st century. J Skin Cancer 2011; 2011: 392151.
3. Cook LM, Hurst DR, Welch DR. Metastasis suppressors and the tumor microenvironment. Semin Cancer Biol 2011; 21: 113-122.
4. Novak M, Jarrett SG, McCorkle JR, et al. Multiple mechanisms underlie metastasis suppressor function of NM23-H1 in melanoma. Naunyn Schmiedebergs Arch Pharmacol 2011; 384: 433-438.
5. Horak CE, Mendoza A, Vega-Valle E, et al. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res 2007; 67: 11751-11759.
6. Kovacevic Z, Richardson DR. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 2006; 27: 2355-2366.
7. Kitowska A, Pawelczyk T. N-myc downstream regulated 1 gene and its place in the cellular machinery. Acta Biochim Pol 2010; 57: 15-21.
8. Guan RJ, Ford HL, Fu Y, et al. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 2000; 60: 749-755.
9. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009; 28: 151-166.
10. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008; 27: 6920-6929.
11. Pizarro A. E-cadherin expression is frequently reduced in infiltrative basal cell carcinoma. J Dermatol 2000; 27: 804-805.
12. Papadavid E, Pignatelli M, Zakynthinos S, et al. Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours. J Pathol 2002; 196: 154-162.
13. DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 2005; 15: 356-363.
14. Griner EM, Theodorescu D. The faces and friends of RhoGDI2. Cancer Metastasis Rev 2012; 31: 519-528.
15. Zhang Y, Zhang B. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res 2006; 66: 5592-5598.
16. Bassani S, Cingolani LA. Tetraspanins: interactions and interplay with integrins. Int J Biochem Cell Biol 2012; 44: 703-708.
17. Romanska HM, Berditchevski F. Tetraspanins in human epithelial malignancies. J Pathol 2011; 223: 4-14.
18. Dong JT, Suzuki H, Pin SS, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996; 56: 4387-4390.
19. Yang X, Wei L, Tang C, et al. KAI1 protein is down-regulated during the progression of human breast cancer. Clin Cancer Res 2000; 6: 3424-3429.
20. Christgen M, Bruchhardt H, Ballmaier M, et al. KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer. Int J Cancer 2008; 123: 2239-2346.
21. Knopeke MT, Ritschdorff ET, Clark R, et al. Building on the foundation of daring hypotheses: using the MKK4 metastasis suppressor to develop models of dormancy and metastatic colonization. FEBS Lett 2011; 585: 3159-3165.
22. Whitmarsh AJ, Davis RJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 2007; 26: 3172-3184.
23. Yoshida BA, Dubauskas Z, Chekmareva MA, et al. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999; 59: 5483-5487.
24. Yamada SD, Hickson JA, Hrobowski Y, et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 2002; 62: 6717-6723.
25. Gelman IH. Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12. Cancer Metastasis Rev 2012; 31: 493-500.
26. Gelman IH. Emerging roles for SSeCKS/Gravin/AKAP12 in the control of cell proliferation, cancer malignancy, and barriergenesis. Genes Cancer 2010; 1: 1147-1156.
27. Carr RA, Taibjee SM, Sanders DSA. Basaloid skin tumours: basal cell carcinoma. Curr Diagn Pathol 2007; 13: 252-272.
28. Kaur P, Mulvaney M, Carlson JA. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol 2006; 28: 293-307.
29. McCarty KS, Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986; 46: 4244s-4248s.
30. Pfaffl MW, Horgan G, Dempfle L. Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30: e36.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
32. Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol 2009; 34: 881-895.
33. Blewitt RW. Why does basal cell carcinoma metastasize so rarely? Int J Dermatol 1980; 19: 144-146.
34. Ro YS, Jeong SJ. Expression of the nucleoside diphosphate kinase in human skin cancers: an immunohistochemical study. J Korean Med Sci 1995; 10: 97-102.
35. Kanitakis J, Euvrard S, Bourchany D, et al. Expression of the nm23 metastasis-suppressor gene product in skin tumors. J Cutan Pathol 1997; 24: 151-156.
36. Tee YT, Chen GD, Lin LY, et al. Nm23-H1: a metastasis-associated gene. Taiwan J Obstet Gynecol 2006; 45: 107-113.
37. Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 2004; 5: 27.
38. Bandyopadhyay S, Wang Y, Zhan R, et al. The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer. Cancer Res 2006; 66: 11983-11990.
39. Bandyopadhyay S, Pai SK, Hirota S, et al. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene 2004; 23: 5675-5681.
40. Strzelczyk B, Szulc A, Rzepko R, et al. Identification of high-risk stage II colorectal tumors by combined analysis of the NDRG1 gene expression and the depth of tumor invasion. Ann Surg Oncol 2009; 16: 1287-1294.
41. Chua MS, Sun H, Cheung ST, et al. Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol 2007; 20: 76-83.
42. Kachhap SK, Faith D, Qian DZ, et al. The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS ONE 2007; 2: e844.
43. Song Y, Oda Y, Hori M, et al. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin. Hum Pathol 2010; 41: 214-222.
44. Okochi H, Kato M, Nashiro K, et al. Expression of tetra-spans transmembrane family (CD9, CD37, CD53, CD63, CD81 and CD82) in normal and neoplastic human keratinocytes: an association of CD9 with alpha 3 beta 1 integrin. Br J Dermatol 1997; 137: 856-863.
45. Wu W, Zhang J, Yang H, et al. Examination of AKAP12 promoter methylation in skin cancer using methylation-sensitive high-resolution melting analysis. Clin Exp Dermatol 2011; 36: 381-385.
46. Mashimo T, Watabe M, Hirota S, et al. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 1998; 95: 11307-11311.
47. Guo C, Liu QG, Zhang L, et al. Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2009; 8: 389-396.
48. Marreiros A, Dudgeon K, Dao V, et al. KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. Oncogene 2004; 24: 637-649.
49. Geradts J, Maynard R, Birrer MJ, et al. Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues. Am J Pathol 1999; 154: 1665-1671.
50. Uzawa K, Ono K, Suzuki H, et al. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis. Clin Cancer Res 2002; 8: 828-835.
51. Miyazaki T, Kato H, Shitara Y, et al. Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma. Cancer 2000; 89: 955-962.
52. Jackson P, Ow K, Yardley G, et al. Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression. Prostate Cancer Prostatic Dis 2003; 6: 174-181.
53. Pizarro A, Benito N, Navarro P, et al. E-cadherin expression in basal cell carcinoma. Br J Cancer 1994; 69: 157-162.